A Phase 3, Multicenter, Randomized, Partially Blinded, Palivizumab- Controlled Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of MK-1654 in Infants and Children at Increased Risk for Severe RSV Disease

Grants and Contracts Details

StatusActive
Effective start/end date3/1/22 → 7/15/24

Funding

  • Merck Sharp & Dohme Corporation: $13,735.00